Curis/Genentech Report Positive Phase II Results For Vismodegib
This article was originally published in The Pink Sheet Daily
Executive Summary
Curis and its partner, Roche's Genentech, plan a 2011 filing for basal cell carcinoma drug vismodegib after announcing positive mid-stage results.
You may also be interested in...
Curis Set For Transformative Year With Erivedge Skin Cancer Approval
Approved nearly six weeks before the March 8 PDUFA date, Erivedge (vismodegib) will be available to treat advanced basal cell cancers in a week or two for about $7,500 a month wholesale, partner Genentech said.
Curis Set For Transformative Year With Erivedge Skin Cancer Approval
Approved nearly six weeks before the March 8 PDUFA date, Erivedge (vismodegib) will be available to treat advanced basal cell cancers in a week or two for about $7,500 a month wholesale, partner Genentech said.
Deals Of The Week: Will Pharmasset’s Windfall Lead To Similar Exits For Other Hepatitis C Biotechs?
Almost two weeks later, people are still talking about ramifications from Gilead’s $11 billion buyout of Pharmasset, but companies such as Roche, Elan and Curis have been active deal makers in recent days.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: